Logo image of INDP

INDAPTUS THERAPEUTICS INC (INDP) Stock Fundamental Analysis

NASDAQ:INDP - Nasdaq - US45339J1051 - Common Stock - Currency: USD

0.8  +0.03 (+3.9%)

Fundamental Rating

2

INDP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While INDP seems to be doing ok healthwise, there are quite some concerns on its profitability. INDP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INDP had negative earnings in the past year.
INDP had a negative operating cash flow in the past year.
INDP had negative earnings in each of the past 5 years.
INDP had a negative operating cash flow in each of the past 5 years.
INDP Yearly Net Income VS EBIT VS OCF VS FCFINDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

INDP has a Return On Assets of -180.75%. This is amonst the worse of the industry: INDP underperforms 88.63% of its industry peers.
Looking at the Return On Equity, with a value of -248.09%, INDP is doing worse than 71.94% of the companies in the same industry.
Industry RankSector Rank
ROA -180.75%
ROE -248.09%
ROIC N/A
ROA(3y)-57.79%
ROA(5y)-92.93%
ROE(3y)-69.11%
ROE(5y)-143.41%
ROIC(3y)N/A
ROIC(5y)N/A
INDP Yearly ROA, ROE, ROICINDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

INDP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INDP Yearly Profit, Operating, Gross MarginsINDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

INDP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, INDP has more shares outstanding
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDP Yearly Shares OutstandingINDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
INDP Yearly Total Debt VS Total AssetsINDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

INDP has an Altman-Z score of -12.36. This is a bad value and indicates that INDP is not financially healthy and even has some risk of bankruptcy.
INDP's Altman-Z score of -12.36 is on the low side compared to the rest of the industry. INDP is outperformed by 79.04% of its industry peers.
INDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.36
ROIC/WACCN/A
WACCN/A
INDP Yearly LT Debt VS Equity VS FCFINDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 3.42 indicates that INDP has no problem at all paying its short term obligations.
With a Current ratio value of 3.42, INDP perfoms like the industry average, outperforming 40.67% of the companies in the same industry.
A Quick Ratio of 3.42 indicates that INDP has no problem at all paying its short term obligations.
With a Quick ratio value of 3.42, INDP perfoms like the industry average, outperforming 42.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
INDP Yearly Current Assets VS Current LiabilitesINDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.97% over the past year.
EPS 1Y (TTM)4.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.41% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.24%
EPS Next 2Y18.4%
EPS Next 3Y18.23%
EPS Next 5Y17.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INDP Yearly Revenue VS EstimatesINDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
INDP Yearly EPS VS EstimatesINDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INDP. In the last year negative earnings were reported.
Also next year INDP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INDP Price Earnings VS Forward Price EarningsINDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INDP Per share dataINDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

INDP's earnings are expected to grow with 18.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.4%
EPS Next 3Y18.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INDP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (2/21/2025, 8:00:01 PM)

0.8

+0.03 (+3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners4.52%
Inst Owner Change5.52%
Ins Owners35.34%
Ins Owner Change13.38%
Market Cap9.61M
Analysts82.5
Price Target8.67 (983.75%)
Short Float %0.48%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.96%
Min EPS beat(2)14.67%
Max EPS beat(2)33.25%
EPS beat(4)4
Avg EPS beat(4)20.84%
Min EPS beat(4)12.85%
Max EPS beat(4)33.25%
EPS beat(8)8
Avg EPS beat(8)20.75%
EPS beat(12)12
Avg EPS beat(12)26.83%
EPS beat(16)13
Avg EPS beat(16)12.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -180.75%
ROE -248.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.79%
ROA(5y)-92.93%
ROE(3y)-69.11%
ROE(5y)-143.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -12.36
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.91%
EPS Next Y3.24%
EPS Next 2Y18.4%
EPS Next 3Y18.23%
EPS Next 5Y17.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.97%
OCF growth 3YN/A
OCF growth 5YN/A